Clinical trials: Anakinra
Acute Pericarditis
Treatment of Acute Pericarditis With Anakinra
The goal of this study is to determine the safety and efficacy of anakinra for the treatment of acute pericarditis when initiated within 6 hours of diagnosis and continued for 3 or 7 days. 1.
- Trial name
- NCT03224585
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Virginia Commonwealth University
Type 1 Diabetes Mellitus
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
The purpose of this study is to determine whether control of inflammatory pathways mediated by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in expression of genes that are otherwise…
- Trial name
- NCT00645840
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
SARS-CoV-2
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the…
- Trial name
- NCT04324021
- Testing
- Emapalumab, Anakinra
- Where
- 12 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Swedish Orphan Biovitrum
Heart Failure
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure
This is an open-label, non-randomized, pilot-study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with heart failure.
- Trial name
- NCT01300650
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Virginia Commonwealth University
Hidradenitis Suppurativa
Anakinra as a Treatment for Hydradenitis Suppurativa
This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS).
- Trial name
- NCT01516749
- Testing
- anakinra
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Kawasaki Disease
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery…
- Trial name
- NCT02179853
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Diego
Allergic Contact Dermatitis
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy
- Trial name
- NCT05498467
- Testing
- Anakinra, Sodium Chloride 9mg/ml Injection
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Herlev and Gentofte Hospital
Pulmonary Hypertension
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension
This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with pulmonary hypertension.
- Trial name
- NCT01479010
- Testing
- Anakinra 100 mg subcutaneously daily
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
Heart Failure
Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)
Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory…
- Trial name
- NCT01936844
- Testing
- Anakinra (high dose), Anakinra (standard dose)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Alcoholic Hepatitis
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis
This multicenter, randomized, double blinded, placebo-controlled clinical trial is focused on novel treatments for severe alcoholic hepatitis (AH), a life-threatening stage of alcoholic liver injury that has a short-term…
- Trial name
- AlcHepNet (NCT04072822)
- Testing
- Anakinra and Zinc, Prednisone
- Where
- 10 sites in United States
- Volunteers
- 147 people
- Sponsor
- Indiana University
Hearing Loss, Sudden
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss
The purpose of this study is to determine if anakinra (an interleukin-1 receptor antagonist) can improve hearing thresholds in patients with sudden sensorineural hearing loss that did not respond to oral steroid therapy.
- Trial name
- SSNHL (NCT02414152)
- Testing
- anakinra
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Andrea Vambutas
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau
Anakinra for Inflammatory Pustular Skin Diseases
Background: Inflammatory pustular skin diseases are a type of autoinflammatory disease in which the immune system attacks the bodys tissues.
- Conditions
- Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
- Trial name
- NCT01794117
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Anterior Cruciate Ligament Tear
IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions
Injury to the knee during sports participation often involves partial or full detachment of the anterior cruciate ligament (abbreviated as ACL). ACL tears cause pain, swelling and inflammation.
- Trial name
- EASI ACL (NCT02930122)
- Testing
- anakinra (150mg), Saline intraarticularly
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cale Jacobs, PhD
Corona Virus Infection
CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection
The overall objective of the study is to determine the therapeutic effect and tolerance of Anakinra in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).
- Trial name
- CORIMUNO-ANA (NCT04341584)
- Testing
- Anakinra
- Where
- France
- Volunteers
- 161 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris